Durable natural killer cell responses after heterologous two-dose Ebola vaccination; Wagstaffe HR, et al. NPJ Vaccines. 2021. DOI: 10.1038/s41541-021-00280-0

Wagstaffe, HR (2019), The Effect of Viral Vaccines on Natural Killer Cell Effector Function. PhD (research paper style) thesis, London School of Hygiene & Tropical Medicine. DOI:

Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells; Tran TTP, et al. PLoS Pathog. 2018. DOI: 10.1371/journal.ppat.1007127

Vaccinating for natural killer cell effector functions; Wagstaffe HR, et al. Clin Transl Immunology. 2018. DOI: 10.1002/cti2.1010



8th EBOVAC2 Newsletter

The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission Approval for Janssen's Ebola vaccine regimen.


7th EBOVAC2 Newsletter

Find out the news from the project in November 2017 here - with the announcement of the Ebovac2 4th General annual meeting planned in Nairobi (Kenya) next January.


6th EBOVAC2 Newsletter

Latest news from the project and interview with Dr Hervé Raoul, Director of Inserm's BSL-4 laboratory.


5th EBOVAC2 Newsletter

Find out what's going on in EBOVAC2, with a special focus on the Burkina Faso training session in January 2018. 


4th EBOVAC2 Newsetter 

News on EBOVAC2 December 2017, click here.


3rd EBOVAC2 Newsletter 

News on EBOVAC2 in October 2017 click here. This issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz clinical site.


2nd EBOVAC2 Newsletter 

Find out what's going on in EBOVAC2 here in June 2017.


1st EBOVAC2 Newsletter 

Get a view on the EBOVAC2 news here in March 2016.


  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings


Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as NotAllowedScriptReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions